Abstract
Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have